CoChat
Sign Up
Cited by 188

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Engineered exosome as targeted lncRNA MEG3 delivery vehicles for osteosarcoma therapy

Huang, Xin, Wu, Wei, Jing, Doudou, Yang, Lingkai, Guo, Haoyu, Wang, Lutong, Zhang, Weiyue, Pu, Feifei, Shao, Zengwu·2022·Journal of Controlled Release
DOI 10.1016/j.jconrel.2022.01.026
Open this paper in CoChat — free account

Abstract

Exosomes as nanosized membrane vesicles, could targeted deliver therapeutic agents by modification with target ligands. Exosome-derived non-coding RNAs play a vital role in the development of tumors. Previous evidences reveal that long non-coding RNA maternally expressed gene 3 (lncRNA MEG3) has anti-tumor properties. Whereas, the inhibitory effects of exosome-derived lncRNA MEG3 in osteosarcoma (OS) remain largely unknown. In this study, we utilize the engineering technology to combine exosome and lncRNA for tumor-targeting therapy of OS. We elucidated the anti-OS effects of lncRNA MEG3, and then prepared the c(RGDyK)-modified and MEG3-loaded exosomes (cRGD-Exo-MEG3). The engineered exosomes cRGD-Exo-MEG3 could deliver more efficiently to OS cells both in vitro and in vivo. In this way, cRGD-Exo-MEG3 facilitate the anti-OS effects of MEG3 significantly, with the help of enhanced tumor-targeting therapy. This study elucidates that engineered exosomes as targeted lncRNA MEG3 delivery vehicles have potentially therapeutic effects for OS.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2022.01.026

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 31

  1. Ottaviani, 2009, The epidemiology of osteosarcoma, Cancer Treat. Res., 152, 3, 10.1007/978-1-4419-0284-9_1 · DOI
  2. Luetke, 2014, Osteosarcoma treatment - where do we stand? A state of the art review, Cancer Treat. Rev., 40, 523, 10.1016/j.ctrv.2013.11.006 · DOI
  3. Katsuda, 2014, The roles of extracellular vesicles in cancer biology: toward the development of novel cancer biomarkers, Proteomics, 14, 412, 10.1002/pmic.201300389 · DOI
  4. Vader, 2014, Extracellular vesicles: emerging targets for cancer therapy, Trends Mol. Med., 20, 385, 10.1016/j.molmed.2014.03.002 · DOI
  5. Wu, 2019, Bone marrow mesenchymal stem cell-derived Exosomal MicroRNA-126-3p inhibits pancreatic Cancer development by targeting ADAM9, Mol Ther Nucleic Acids, 16, 229, 10.1016/j.omtn.2019.02.022 · DOI
  6. Marote, 2016, MSCs-derived exosomes: cell-secreted Nanovesicles with regenerative potential, Front. Pharmacol., 7, 231, 10.3389/fphar.2016.00231 · DOI
  7. Lai, 2014, Dynamic biodistribution of extracellular vesicles in vivo using a multimodal imaging reporter, ACS Nano, 8, 483, 10.1021/nn404945r · DOI
  8. Jia, 2018, NRP-1 targeted and cargo-loaded exosomes facilitate simultaneous imaging and therapy of glioma in vitro and in vivo, Biomaterials, 178, 302, 10.1016/j.biomaterials.2018.06.029 · DOI · Paper page
  9. Yuan, 2018, GSH-activated light-up near-infrared fluorescent probe with high affinity to α(v)β(3) integrin for precise early tumor identification, ACS Appl. Mater. Interfaces, 10, 30994, 10.1021/acsami.8b09841 · DOI
  10. Lu, 2018, Enhancing osteosarcoma killing and CT imaging using ultrahigh drug loading and NIR-responsive bismuth sulfide@mesoporous silica nanoparticles, Adv Healthc Mater, 7, 10.1002/adhm.201800602 · DOI
  11. Wang, 2019, cRGD-functionalized nanoparticles for combination therapy of anti-endothelium dependent vessels and anti-vasculogenic mimicry to inhibit the proliferation of ovarian cancer, Acta Biomater., 94, 495, 10.1016/j.actbio.2019.06.039 · DOI
  12. Gu, 2019, cRGD-decorated biodegradable polytyrosine nanoparticles for robust encapsulation and targeted delivery of doxorubicin to colorectal cancer in vivo, J. Control. Release, 301, 110, 10.1016/j.jconrel.2019.03.005 · DOI
  13. Lv, 2017, A systematic review and meta-analysis of the association between long non-coding RNA polymorphisms and cancer risk, Mutation Res.-Rev. in Mutation Res., 771, 1, 10.1016/j.mrrev.2016.10.002 · DOI
  14. Ponting, 2009, Evolution and functions of long noncoding RNAs, Cell, 136, 629, 10.1016/j.cell.2009.02.006 · DOI · Paper page
  15. Wang, 2011, Molecular mechanisms of long noncoding RNAs, Mol. Cell, 43, 904, 10.1016/j.molcel.2011.08.018 · DOI
  16. Gibb, 2011, The functional role of long non-coding RNA in human carcinomas, Mol. Cancer, 10, 10.1186/1476-4598-10-38 · DOI
  17. Tian, 2015, Decreased expression of long non-coding RNA MEG3 acts as a potential predictor biomarker in progression and poor prognosis of osteosarcoma, Int. J. Clin. Exp. Pathol., 8, 15138
  18. Zhang, 2016, Long noncoding RNA MEG3 is downregulated in cervical cancer and affects cell proliferation and apoptosis by regulating miR-21, Cancer Biology & Therapy, 17, 104, 10.1080/15384047.2015.1108496 · DOI · Paper page
  19. Salmena, 2011, A ceRNA hypothesis: the Rosetta stone of a hidden RNA language?, Cell, 146, 353, 10.1016/j.cell.2011.07.014 · DOI · Paper page
  20. Emst, 2013, Identification and function of long non-coding RNA, Front. Cell. Neurosci., 7
  21. Huang, 2018, Association between long non-coding RNA polymorphisms and cancer risk: a meta-analysis, Biosci. Rep., 38, 10.1042/BSR20180365 · DOI
  22. Jin, 2018, Long noncoding RNA MEG3 regulates LATS2 by promoting the ubiquitination of EZH2 and inhibits proliferation and invasion in gallbladder cancer, Cell Death Dis., 9, 10.1038/s41419-018-1064-1 · DOI
  23. Shen, 2018, Long non-coding RNA MEG3 functions as a competing endogenous RNA to regulate HOXA11 expression by sponging miR-181a in multiple myeloma, Cell. Physiol. Biochem., 49, 87, 10.1159/000492846 · DOI
  24. Zhang, 2017, MEG3 suppresses human pancreatic neuroendocrine tumor cells growth and metastasis by Down-regulation of Mir-183, Cell. Physiol. Biochem., 44, 345, 10.1159/000484906 · DOI
  25. Zheng, 2018, Long noncoding RNA MEG3 suppresses liver cancer cells growth through inhibiting beta-catenin by activating PKM2 and inactivating PTEN, Cell Death Dis., 9, 253, 10.1038/s41419-018-0305-7 · DOI
  26. Shi, 2018, MEG3 inhibits proliferation and invasion and promotes apoptosis of human osteosarcoma cells, Oncol. Lett., 15, 1917
  27. Zhang, 2017, MEG3 long non-coding RNA prevents cell growth and metastasis of osteosarcoma, Bratisl. Lek. Listy, 118, 632
  28. Wang, 2018, Knockdown of lncRNA MEG3 inhibits viability, migration, and invasion and promotes apoptosis by sponging miR-127 in osteosarcoma cell, J. Cell. Biochem., 119, 669, 10.1002/jcb.26230 · DOI
  29. Sun, 2014, Potential of cancer cell-derived exosomes in clinical application: a review of recent research advances, Clin. Ther., 36, 863, 10.1016/j.clinthera.2014.04.018 · DOI
  30. Xu, 2019, microRNA-16-5p-containing exosomes derived from bone marrow-derived mesenchymal stem cells inhibit proliferation, migration, and invasion, while promoting apoptosis of colorectal cancer cells by downregulating ITGA2, J. Cell. Physiol., 234, 21380, 10.1002/jcp.28747 · DOI
  31. Xie, 2019, Exosomes derived from microRNA-101-3p-overexpressing human bone marrow mesenchymal stem cells suppress oral cancer cell proliferation, invasion, and migration, Mol. Cell. Biochem., 458, 11, 10.1007/s11010-019-03526-7 · DOI

Cited by

Sorted by citations

See all 188

Metadata

Authors
Huang, X., Wu, W., Jing, D., Yang, L., Guo, H., Wang, L., Zhang, W., Pu, F., & Shao, Z.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2022-03
Volume
343
Pages
107-117
ISSN
0168-3659
DOI
10.1016/j.jconrel.2022.01.026
Cited by
188
References
3
Language
en
Licence
Funders
  • National Natural Science Foundation of China (91649204)
  • National Key Research and Development Program of China (2016YFC1100100)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review